OncLive SOSS

Authors

Sumanta K. Pal, MD, FASCO

Latest:

Dr Pal on the Preliminary Efficacy of DFF332 in Advanced ccRCC

Sumanta Kumar Pal, MD, FASCO, discusses preliminary findings from a phase 1 dose-escalation study of DFF332 in patients with advanced ccRCC.

Sujith R. Kalmadi, MD

Latest:

Role of a Pharmacist in Developing Treatment Pathways and Educating Patients

Ryan Haumschild, PharmD, MS, MBA, reflects on how oncologic pharmacists can help to develop treatment pathways and educate patients on precision medicine.

Emma Searle, MD

Latest:

Dr. Searle on Initial Results From the MajesTEC-2 Trial in Multiple Myeloma

Emma Searle, MD, discusses early findings from cohort E of the phase 1b MajesTEC-2 trial (NCT04722146) evaluating teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) and lenalidomide (Revlimid) in multiple myeloma.

Pei-Ling Chen, MD, PhD

Latest:

Dr. Chen Explores Possible Genomic Basis for Racial Disparities in CTCL Outcomes

Pei-Ling Chen, MD, PhD, discusses genomic findings that may explain poorer outcomes for Black patients with CTCL.

Rene Adam, MD, PhD

Latest:

Dr Adam on Efforts to Reduce Recurrence Risk in CRC Liver Metastases

Rene Adam, MD, PhD, discusses future research aimed at reducing the risk of recurrence in patients with unresectable colorectal liver metastases

R. Jonathan Henderson, MD

Latest:

Dr Henderson on Incorporating Immunotherapy Agents into Practice in Bladder Cancer

R. Jonathan Henderson, MD, discusses incorporating immunotherapy agents into practice in patients with bladder cancer.

Manish A. Shah, MD, FASCO, Weill Cornell Medicine/New York-Presbyterian Hospital

Latest:

Dr. Shah on the Importance of Genetic Testing in GI Cancer

Manish A Shah, MD, discusses the importance of genetic testing in gastrointestinal cancer.

Latest:

Dr. Kim on the Utility of Atezolizumab/Bevacizumab in HCC

Joseph Kim, MD, on the utility of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Ze'ev Ronai, PhD

Latest:

Dr Ronai on Key Advances in Melanoma Treatment Approaches

Ze'ev Ronai, PhD, discusses key advancements in the treatment of patients with melanoma, including the discovery of NRAS and BRAF mutations, as well as the development of immunotherapy approaches.

Kelly Garvin, MA, BSN, RN

Latest:

Garvin on the Benefits of CAR T-Cell Therapy in Non-Hodgkin Lymphoma

Kelly Garvin, MA, BSN, RN, discusses the impact of CAR T-cell therapy on the treatment of patients with non-Hodgkin lymphoma.

Lionel Kankeu Fonkoua, MD

Latest:

Dr Fonkoua on Addressing Barriers to Cancer Clinical Trial Access

Lionel A. Kankeu Fonkoua, MD, discusses the importance of addressing barriers to clinical trial access that patients with cancer may face and increasing patient access to routine, primary care.

Meghan Thompson, MD

Latest:

Dr. Thompson on the Rationale for the BRUIN Study in Richter Transformation

Meghan Thompson, MD, discusses the rationale for the phase 1/2 BRUIN study in patients with Richter transformation.

Latest:

Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer

Palbociclib plus anti-HER2 and endocrine therapy improved progression-free survival in hormone receptor–positive, HER2-positive metastatic breast cancer.

Eirwen M. Miller, MD

Latest:

Dr Miller on the Importance of Patient Advocacy in Gynecologic Oncology

Eirwen M. Miller, MD, discusses the importance of advocating for women in gynecologic oncology on International Women’s Day.

Latest:

Truong on the Rationale for Investigating ERK2 Substrate Binding Modalities in MPNs

Billy Truong discusses the rationale for investigating the functions of ERK2 substrate binding modalities in patients with myeloproliferative neoplasms.

Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center

Latest:

Using Systemic Therapy to Treat HER2+ Breast Cancer

Closing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.

Kathryn Gold, MD, UC San Diego Health

Latest:

Dr. Gold on Current Unmet Needs in Squamous Cell Carcinoma of the Lung

Kathryn A. Gold, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses current unmet needs in squamous cell carcinoma of the lung.

Toufic A. Kachaamy, MD

Toufic Kachaamy, MD, FASGE, AGAF, is an

Latest:

Leveraging Immunotherapy in GI Malignancies: Looking to the Future

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.

Kelly K. Hunt, MD, FACS, FSSO

Latest:

Dr. Hunt on Axillary Reverse Mapping in Breast Cancer

Kelly K. Hunt, MD, FACS, FSSO, discusses technical considerations for axillary reverse mapping in breast cancer for the reduction or prevention of lymphedema.

Elias K. Mai, MD

Latest:

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Dr. Elias K. Mai presents final progression-free survival results from the Phase 3 GMMG-HD7 trial, demonstrating that adding isatuximab to lenalidomide, bortezomib, and dexamethasone (Isa-RVd) significantly improves minimal residual disease negativity and reduces the risk of progression or death in transplant-eligible patients with newly diagnosed multiple myeloma.